Key result
Elevated mean platelet volume is associated with increased platelet reactivity and serves as a biomarker for predicting cardiovascular risk, ischemic stroke in atrial fibrillation, and adverse outcomes following percutaneous coronary intervention.
Mean platelet volume is a readily available, inexpensive biomarker that may help predict cardiovascular risk, restenosis after PCI, and ischemic stroke in atrial fibrillation.
Increased mean platelet volume (MPV) is associated with platelet reactivity and is a predictor of cardiovascular risk and unprovoked nervous thromboembolism. Mean platelet volume is a precise measure of platelet size. Studies have reported the use of MPV as a biomarker for predicting ischemic stroke in atrial fibrillation patients as well as in anticoagulant prescription and rhythm-control therapy. Moreover, MPV may predict cardiovascular event outcome following percutaneous coronary intervention in patients with coronary artery disease. MPV may predict residual platelet reactivity in dual antiplatelet therapy. Factors influencing MPV result were discussed. This review centered on the reports that MPV may be a biomarker of risk and prognosis of prevalent heart diseases.
No takes yet. Share an insight, caveat, or question.
Okoroiwu et al. (2018) conducted a review in Cardiovascular disease. Mean platelet volume was evaluated. Elevated mean platelet volume is associated with increased platelet reactivity and serves as a biomarker for predicting cardiovascular risk, ischemic stroke in atrial fibrillation, and adverse outcomes following percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: